AMADIS
1.5.2022 07:02:07 CEST | Business Wire | Press release
Amadis , a leading payment software and consulting provider, today announced a partnership agreement with Softpay.io to provide its Universal EMV Level 2 Framework & pre-certified Kernels for integration into Softpay’s new Tap-to-Pay service. Softpay’s revolutionary Tap-to-Pay service can be downloaded into any Android device and turn into a full payment card acceptance terminal. Softpay’s solution provides merchants with greater flexibility and future proofing capabilities, while lowering costs and creating new revenue opportunities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220430005009/en/
The Amadis solution is a component of its Amadis One software framework composed of an EMV L2 Framework and ecosystem supporting any EMV Contactless Kernel. It enables Softpay’s service to seamlessly accept EMV payments on Android-based COTS devices with NFC capabilities, reduces the time for Softpay to roll out new products and provide payment acceptance of any payment schemes, on its new mobile payments platform. Amadis One software framework is the first solution to enable nexo (ISO 202022) standards on Tap-to-Pay platforms.
“Softpay’s solution helps us to transform the shopping experience, enabling our store associates to check out customers anywhere in-store, or at curbside,” said Thomas Grane, CIO, at Matas. “The solution drives new sales opportunities, and enables a more efficient, personalized customer experience.”
Softpay’s Tap-to-Pay is impacting several industries, including retailers and QSRs, who can operate more efficiently. Staff can accept payments, while multi-tasking anywhere in-store, or at curbside pickup locations. Transit companies can drive new points of sale by instantly offering and processing new and upgraded tickets, while passengers are on board trains and buses.
“Softpay’s Tap-to-Pay service provides innovative new experiences to retail, transportation and the QSR industries, and our Amadis One software framework helps them bring products to market faster,” said Emmanuel Haydont, CEO and co-founder, Amadis. “Amadis One commoditizes complex payment processes, freeing up resources for merchants to innovate, accelerating time to market and reducing costs, while enhancing the customer experience.”
“By integrating Amadis One with our Tap-to-Pay solution, we enable merchants to revolutionize the customer experience, while lowering their costs and providing greater flexibility,” said Craig Jacoby, CEO, Softpay.io. “By enabling tap-to-pay transactions on smartphones, merchant fees for card present transactions are lowered, new customer points of interactions (POIs) are generated, creating innovative new ways to interact with customers, while processing transactions.”
About Softpay.io
Softpay was founded in 2019 to take advantage of the new Visa and Mastercard specifications for payment terminals which enabled Softpay to develop a mobile application that allows merchants to turn a regular phone into a contactless payment terminal with PIN. Softpay has grown into a company with more than 30 employees and is headquartered in Copenhagen, Denmark. Softpay has received more than €9 mill in funding and the ambition is to be one of the leading global providers of tap-to-phone solutions. Leading European payment companies have decided to partner with Softpay and Softpay is now focusing on North America as well.
About Amadis
Amadis is a leader in payment card acceptance software technology, with its software running on more than 50 million devices worldwide. The company provides state-of-the-art software products, frameworks and solutions for global merchants, payment terminal manufacturers and payment processors. Amadis provides merchants with the industry’s broadest range of EMV card processing options using custom or commercially available technology, independent of hardware, operating system or geography. The company brings an elite, experienced software team to the industry and enables solutions for international acceptors in over 23 countries. Learn more at www.amadis.ca .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220430005009/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom